Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib Editorial Comment

被引：0
|
作者：
Penson, David F.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 188卷 / 01期
关键词：
D O I：
10.1016/j.juro.2012.03.096
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 69
页数：2
相关论文
共 50 条
  • [1] Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib
    Casciano, Roman
    Chulikavit, Maruit
    Di Lorenzo, Giuseppe
    Liu, Zhimei
    Baladi, Jean-Francois
    Wang, Xufang
    Robertson, Justin
    Garrison, Lou
    VALUE IN HEALTH, 2011, 14 (06) : 846 - 851
  • [2] ECONOMIC EVALUATION OF EVEROLIMUS VERSUS SORAFENIB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA AFTER FAILURE ON TREATMENT WITH SUNITINIB
    Casciano, R.
    Chulikavit, M.
    Di Lorenzo, G.
    Stern, L.
    Liu, Z.
    Wang, X.
    Garay, C.
    Garrison, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 295 - 296
  • [3] Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma Comment
    Penson, David F.
    JOURNAL OF UROLOGY, 2009, 181 (03): : 1067 - 1067
  • [4] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [5] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [6] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [7] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [8] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [9] ECONOMIC EVALUATION OF SUNITINIB FOR THE FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Novikov, I
    VALUE IN HEALTH, 2012, 15 (04) : A222 - A222
  • [10] Comparative efficacy of sunitinib versus sorafenib as the first-line treatment for patients with metastatic renal cell carcinoma.
    Park, Seongjoon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongchel
    Ahn, Jin-Hee
    Lee, Dae Ho
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345